New JAK3 blocker ZL-82 passes first safety check in healthy volunteers
NCT ID NCT06432738
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new experimental drug, ZL-82, in 41 healthy adults to see if it is safe and how the body processes it. The drug targets a protein involved in immune signaling. Researchers also checked whether ZL-82 affects the heart's electrical activity. The results will help decide safe doses for future studies in patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PERSON are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Medical Shandong Hospital of Traditional Chinese Medicine
Zibo, Shandong, 255000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.